

Please add the following new claims:

--3. The method of claim 2 wherein said ovarian epithelial cells are treated with said agent using an *in vivo* test.--

--4. The method of claim 2 wherein said test is conducted *in vitro*.--

--5. The method of claim 2 wherein said measured TGF- $\beta$  expression is upregulation of TGF- $\beta$  2 or TGF- $\beta$  3.--

--6. The method of claim 5 further comprising formulating a regimen wherein said regimen comprises a daily dosage of said composition for use by human female subject.--

#### REMARKS

Applicant has amended claim 1 and added new claims 3-6.

In response to the rejection under 35 U.S.C. §112, ¶1, relating to the claim phrase “agent based on its ability to upregulate TGF- $\beta$  expression in the ovarian epithelium,” applicant has amended claim 1 to further specify that the method for selecting the agent involves testing for expression of TGF- $\beta$  in ovarian epithelial cells by exposing cells to the agent and measuring the resulting expression of TGF- $\beta$ . The application states at page 57, lines 24-29 that an agent is selected based on tests for expression of TGF- $\beta$  expression. The specification gives specific examples of the tests that can be used by stating that the candidate agents “are tested by methods described in Examples 6, 7, 8, 9, 12, and/or 13 to determine their ability to induce biologic effects in ovarian epithelial cells.” (Application, pg. 57, lns. 27-29).

Example 6 provides a method of TGF- $\beta$  testing based on administration of the agents to women at least one month prior to a scheduled surgery for removal of ovaries. The ovaries are then evaluated for TGF- $\beta$  expression. Example 7 provides a method of *in vitro* TGF- $\beta$  testing on human ovarian epithelial cells. Example 12 provides further details on *in vitro*